Loading...
Loading...
RVNC| Name | Value |
|---|---|
| Revenues | 58.1M |
| Cost of Revenue | 21.3M |
| Gross Profit | 36.8M |
| Operating Expense | 102.3M |
| Operating I/L | -65.5M |
| Other Income/Expense | -11.0M |
| Interest Income | 3.1M |
| Pretax | -67.3M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -67.3M |
Revance Therapeutics, Inc. is a biotechnology company specializing in the development, manufacturing, and commercialization of neuromodulators for aesthetic and therapeutic purposes. The company's lead drug candidate, DaxibotulinumtoxinA, has completed phase III clinical trials for treating glabellar lines and cervical dystonia, with ongoing phase II trials for various facial lines, upper limb spasticity, and plantar fasciitis. Additionally, the company is developing DaxibotulinumtoxinA for migraine treatment and a topical program for multiple indications. Revance also has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA, a biosimilar to BOTOX.
